Chronic Myeloid Leukemia

A clinical study reveals that combining third-generation tyrosine kinase inhibitors with azacitidine effectively treats chronic myeloid leukemia, showing promising patient outcomes.

The FDA approves generic dasatinib tablets, enhancing access and affordability for treating chronic myeloid leukemia and acute lymphoblastic leukemia.

New research reveals that CD26+ leukemia stem cell levels at diagnosis predict treatment response in chronic myeloid leukemia patients, enhancing TKI therapy strategies.

The FDA reviews XS003, a new nilotinib formulation for CML, promising improved safety and convenience for patients.

Tagraxofusp shows manageable safety but limited efficacy in chronic myelomonocytic leukemia (CMML), with ongoing studies exploring combination therapies for better outcomes.

A new drug application for Dasynoc was not approved for patients with chronic myeloid leukemia and acute lymphoblastic leukemia.

Navtemadlin, a novel MDM2 inhibitor, demonstrated potential in treating relapsed or refractory myelofibrosis in the phase 3 BOREAS trial.

Asciminib has gained accelerated approval from the FDA for the treatment of patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

Careful management by a team of specialists is needed to balance disease control and fetal health in patients with CML who are pregnant or trying to become prengant.

Ongoing research is exploring new molecular targets and targeted therapies for this challenging disease.

The FDA granted priority review to asciminib for the treatment of newly diagnosed, Philadelphia chromosome-positive, chronic phase chronic myeloid leukemia.

The BCR-ABL tyrosine kinase inhibitor TERN-701 has been granted an orphan drug designation from the FDA for the treatment of chronic myeloid leukemia.

The FDA has accepted Xspray Pharma's resubmitted application for Dasynoc, a potential new treatment for chronic myeloid leukemia and acute lymphoblastic leukemia.

Findings from the phase 3 ASC4FIRST trial showed that asciminib demonstrated encouraging major molecular response in patients with Philadelphia chromosome-positive chronic myeloid leukemia.

A comparison of asciminib and bosutinib demonstrated greater efficacy and safety/tolerability with asciminib for patients with chronic phase chronic myeloid leukemia.

Results from the phase 1b study of Orca-T with myeloblative chemotherapy conditioning showed the feasibility of the therapy in younger and older patients with hematologic malignancies.

A phase 1 trial of TERN-701 for chronic myeloid leukemia plans to start patient screening in December 2023, with initial data expected to be released in the second half of 2024.

During a Targeted Oncology™ Case-Based Roundtable™ event, Kendra Sweet, MD, and participants discussed dosing and toxicity concerns with tyrosine kinase inhibitors in patients with chronic-phase chronic myeloid leukemia.